For example, Nigro et al. reported a high frequency of complex TP53 mutations, including TP53 c.817 C>T, in the metastases from breast cancer patients.40 Several TP53 mutations, including TP53 c.817 C>T, were also reported during disease progression in acute myeloid leukemia patients41 or in prostatic small cell neuroendocrine carcinoma, where accumulation of p53 was observed in 56% of small cell carcinomas.42 Other than P53, mutations of AR, PTEN were also detected both in 33.3% (5/15) of the CTC samples. This evidence concerns the gene AR and breast carcinoma.